$8.2
Revenue is down for the last 2 quarters, 2.13B → 1.94B (in $), with an average decrease of 9.0% per quarter
Netprofit is up for the last 2 quarters, -410.0M → -201.0M (in $), with an average increase of 104.0% per quarter
In the last 1 year, Bausch Health Companies Inc has experienced a drawdown of -14.2%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 11.8%
In the last 3 years, Zoetis Inc - Class A has given 17.8% return, outperforming this stock by 75.0%
2.07%
Downside
Day's Volatility :3.08%
Upside
1.03%
51.22%
Downside
52 Weeks Volatility :60.9%
Upside
19.84%
Period | Bausch Health Companies Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -10.95% | 0.7% | -6.8% |
6 Months | 6.62% | -8.3% | -6.0% |
1 Year | -14.21% | -1.9% | -4.6% |
3 Years | -57.15% | 25.3% | 25.9% |
Market Capitalization | 3.0B |
Book Value | - $2.2 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.97 |
PEG Ratio | 0.63 |
Wall Street Target Price | 13.1 |
Profit Margin | -4.38% |
Operating Margin TTM | 16.92% |
Return On Assets TTM | 3.16% |
Return On Equity TTM | -17750.0% |
Revenue TTM | 8.2B |
Revenue Per Share TTM | 22.48 |
Quarterly Revenue Growth YOY | 1.4000000000000001% |
Gross Profit TTM | 5.8B |
EBITDA | 2.7B |
Diluted Eps TTM | -0.97 |
Quarterly Earnings Growth YOY | 1.12 |
EPS Estimate Current Year | 3.29 |
EPS Estimate Next Year | 3.78 |
EPS Estimate Current Quarter | 0.72 |
EPS Estimate Next Quarter | 0.79 |
What analysts predicted
Upside of 59.76%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 8.7B | ↓ 9.82% |
Net Income | 2.4B | ↓ 199.79% |
Net Profit Margin | 27.56% | ↑ 52.46% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↓ 3.94% |
Net Income | -4.1B | ↓ 272.55% |
Net Profit Margin | -49.5% | ↓ 77.06% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.6B | ↑ 2.64% |
Net Income | -1.8B | ↓ 56.89% |
Net Profit Margin | -20.79% | ↑ 28.71% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↓ 6.67% |
Net Income | -560.0M | ↓ 68.68% |
Net Profit Margin | -6.98% | ↑ 13.81% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↑ 5.07% |
Net Income | -948.0M | ↑ 69.29% |
Net Profit Margin | -11.24% | ↓ 4.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↓ 4.6% |
Net Income | -225.0M | ↓ 76.27% |
Net Profit Margin | -2.8% | ↑ 8.44% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 4.03% |
Net Income | 69.0M | ↓ 63.3% |
Net Profit Margin | 3.14% | ↓ 5.77% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 12.66% |
Net Income | -69.0M | ↓ 200.0% |
Net Profit Margin | -3.6% | ↓ 6.74% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 1.51% |
Net Income | -145.0M | ↑ 110.14% |
Net Profit Margin | -7.45% | ↓ 3.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 5.08% |
Net Income | 399.0M | ↓ 375.17% |
Net Profit Margin | 19.5% | ↑ 26.95% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.1B | ↑ 4.35% |
Net Income | -410.0M | ↓ 202.76% |
Net Profit Margin | -19.2% | ↓ 38.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 8.95% |
Net Income | -201.0M | ↓ 50.98% |
Net Profit Margin | -10.34% | ↑ 8.86% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 37.5B | ↓ 13.86% |
Total Liabilities | 31.6B | ↓ 21.65% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 32.5B | ↓ 13.35% |
Total Liabilities | 29.7B | ↓ 5.95% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 33.9B | ↑ 4.22% |
Total Liabilities | 32.7B | ↑ 10.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 31.2B | ↓ 7.87% |
Total Liabilities | 30.6B | ↓ 6.52% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 29.2B | ↓ 6.4% |
Total Liabilities | 29.2B | ↓ 4.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.7B | ↓ 12.04% |
Total Liabilities | 25.4B | ↓ 13.03% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 29.2B | ↓ 0.17% |
Total Liabilities | 29.2B | ↓ 0.51% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 29.1B | ↓ 0.38% |
Total Liabilities | 29.2B | ↓ 0.02% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 28.2B | ↓ 3.16% |
Total Liabilities | 27.9B | ↓ 4.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 26.3B | ↓ 6.65% |
Total Liabilities | 25.9B | ↓ 7.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.7B | ↓ 2.33% |
Total Liabilities | 25.4B | ↓ 1.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 25.4B | ↓ 0.94% |
Total Liabilities | 25.3B | ↓ 0.5% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↑ 9.73% |
Investing Cash Flow | 2.9B | ↓ 2409.6% |
Financing Cash Flow | -5.0B | ↑ 152.83% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 34.45% |
Investing Cash Flow | -196.0M | ↓ 106.79% |
Financing Cash Flow | -1.4B | ↓ 72.74% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 0.0% |
Investing Cash Flow | -419.0M | ↑ 113.78% |
Financing Cash Flow | 1.4B | ↓ 206.65% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 25.98% |
Investing Cash Flow | -261.0M | ↓ 37.71% |
Financing Cash Flow | -2.3B | ↓ 258.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.4B | ↑ 28.35% |
Investing Cash Flow | 409.0M | ↓ 256.7% |
Financing Cash Flow | -1.5B | ↓ 34.05% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 24.0M | ↓ 95.74% |
Investing Cash Flow | -80.0M | ↓ 113.61% |
Financing Cash Flow | 275.0M | ↓ 123.77% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -63.0M | ↓ 362.5% |
Investing Cash Flow | -56.0M | ↓ 30.0% |
Financing Cash Flow | 468.0M | ↑ 70.18% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 123.0M | ↓ 295.24% |
Investing Cash Flow | -58.0M | ↑ 3.57% |
Financing Cash Flow | -630.0M | ↓ 234.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.3B | ↓ 1126.83% |
Investing Cash Flow | -167.0M | ↑ 187.93% |
Financing Cash Flow | -36.0M | ↓ 94.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 154.0M | ↓ 67.58% |
Investing Cash Flow | -78.0M | - |
Financing Cash Flow | -142.0M | ↓ 48.55% |
Sell
Neutral
Buy
Bausch Health Companies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bausch Health Companies Inc | 9.32% | 6.62% | -14.21% | -57.15% | -62.82% |
![]() Neurocrine Biosciences Inc. | -13.93% | -29.12% | -3.47% | -27.45% | -9.1% |
![]() Zoetis Inc. | -9.22% | 4.07% | -2.4% | 17.83% | 90.83% |
![]() Viatris Inc. | -2.24% | -18.59% | -24.19% | -44.0% | -44.0% |
![]() Catalent, Inc. | -25.72% | -28.72% | -64.37% | -51.42% | -6.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bausch Health Companies Inc | 71.75 | NA | 0.63 | 3.29 | -177.5 | 0.03 | 0.0 | -2.2 |
![]() Neurocrine Biosciences Inc. | 145.34 | 145.34 | 1.87 | 2.1 | 0.04 | 0.08 | 0.0 | 17.28 |
![]() Zoetis Inc. | 36.41 | 36.41 | 3.53 | 5.4 | 0.45 | 0.13 | 0.01 | 9.72 |
![]() Viatris Inc. | 5.8 | 5.8 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.45 |
![]() Catalent, Inc. | 15.88 | 15.88 | 1.18 | 1.37 | 0.09 | 0.04 | 0.0 | 27.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bausch Health Companies Inc | Buy | $3.0B | -62.82% | 71.75 | -4.38% |
![]() Neurocrine Biosciences Inc. | Buy | $8.8B | -9.1% | 145.34 | 4.0% |
![]() Zoetis Inc. | Buy | $74.4B | 90.83% | 36.41 | 25.59% |
![]() Viatris Inc. | Hold | $10.9B | -44.0% | 5.8 | 12.05% |
![]() Catalent, Inc. | Buy | $6.5B | -6.08% | 15.88 | 8.62% |
ICAHN CARL C
Paulson & Company Inc
Franklin Resources Inc
Goldentree Asset Management LP
Natixis SA
Hudson Bay Capital Management LP
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
Organization | Bausch Health Companies Inc |
Employees | 19900 |
CEO | Mr. Thomas J. Appio |
Industry | Health Technology |